Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bertilimumab - Immune Pharmaceuticals

Drug Profile

Bertilimumab - Immune Pharmaceuticals

Alternative Names: Anti-eotaxin human monoclonal antibody; CAT-213; iCo-008

Latest Information Update: 01 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Cambridge Antibody Technology; iCo Therapeutics; Immune Pharmaceuticals Inc
  • Class Antiallergics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Chemokine CCL11 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bullous pemphigoid
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bullous pemphigoid; Crohn's disease; Ulcerative colitis
  • Preclinical Non-alcoholic steatohepatitis
  • No development reported Allergic conjunctivitis; Asthma; Atopic dermatitis; Wet age-related macular degeneration
  • Discontinued Allergic rhinitis; Ovarian cancer

Most Recent Events

  • 01 Oct 2019 Alexion to acquire anti-eotaxin-1 antibody from Immune Pharmaceuticals
  • 18 Dec 2018 Bertilimumab - Immune Pharmaceuticals is available for licensing as of 18 Dec 2018. www.immunepharma.com
  • 28 Sep 2018 No recent reports of development identified for phase-I development in Atopic-dermatitis in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top